Trials / Completed
CompletedNCT04233060
A Study of CS3005 in Advanced Solid Tumors
A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- CStone Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects with Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS3005 | CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years) |
Timeline
- Start date
- 2020-01-10
- Primary completion
- 2021-01-31
- Completion
- 2021-02-17
- First posted
- 2020-01-18
- Last updated
- 2022-04-27
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04233060. Inclusion in this directory is not an endorsement.